Hyperion DeFi (NASDAQ: HYPD) recently received a number of ratings updates from brokerages and research firms:
- 8/18/2026 – Hyperion DeFi was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
- 8/13/2026 – Hyperion DeFi had its price target raised by Cantor Fitzgerald from $6.60 to $7.10. They now have an “overweight” rating on the stock.
- 8/12/2026 – Hyperion DeFi was downgraded by Zacks Research from “hold” to “strong sell”.
- 8/11/2026 – Hyperion DeFi had its “buy” rating reaffirmed by Chardan Capital. They now have a $7.30 price target on the stock.
- 7/14/2026 – Hyperion DeFi was upgraded by Zacks Research from “strong sell” to “hold”.
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
See Also
- Five stocks we like better than Hyperion DeFi
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Hyperion DeFi Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperion DeFi Inc and related companies with MarketBeat.com's FREE daily email newsletter.
